2020-02-04
NextCell to present its progress at Swiss Nordic Bio 2020
NextCell Pharma AB ("NextCell") presented, in December 2019, efficacy data of ProTrans stem cells in an interim analysis of the ongoing phase I/II trial, ProTrans-1. Patients receiving medium or high dose of ProTrans showed a statistically significant effect as compared to low dose. The company will present data at Swiss Nordic Bio 2020, on February 6 in Zurich.
Swiss Nordic Bio is a partnering and investor conference aimed at connecting healthcare innovations, investors and industry. For NextCell this is an opportunity to inform international investors and potential collaborators about
NextCell Pharma AB ("NextCell") presented, in December 2019, efficacy data of ProTrans stem cells in an interim analysis of the ongoing phase I/II trial, ProTrans-1. Patients receiving medium or high dose of ProTrans showed a statistically significant effect as compared to low dose. The company w...
Read moreRead more2020-01-31
Interim Report 1 2019/2020
NextCell Pharma AB today publish the Interim Report 1 for the period September 1 - November 30, 2019.
“NextCell”, “NXTCL” or “Company” refer to NextCell Pharma AB with organization number 556965-8361.The amount in brackets refers to the corresponding period in the previous year. Note that the Company’s fiscal year is September 1-August 31.
First quarter (2019-09-01 until 2019-11-30)
· Operating income amounted to SEK 1 222 087 (73 745).
· Operating result amounted to SEK -3 755 926 (-5 440 809).
· Earnings per share* amounted to SEK -0,20 (-0,38).
· Cash and bank
NextCell Pharma AB today publish the Interim Report 1 for the period September 1 - November 30, 2019.
“NextCell”, “NXTCL” or “Company” refer to NextCell Pharma AB with organization number 556965-8361.The amount in brackets refers to the corresponding period in the previous year. Note that the Com...
Read moreRead more2019-12-11
Extended permission from the Medical Products Agency
NextCell Pharma AB ("NextCell") announces that they have been granted with an extended wholesale distribution authorization from the Medical Products Agency. In October, the NextCell operation were subject to a regular inspection by the Medical Products Agency which resulted in the wholesale distribution authorization being extended for five years.
The wholesale distribution authorization allows NextCell to store and distribute the study drug, ProTrans, for use in the clinical trials.
In addition to the Medical Products Agency, the Health and Care Inspectorate (IVO) acts as supervisory
NextCell Pharma AB ("NextCell") announces that they have been granted with an extended wholesale distribution authorization from the Medical Products Agency. In October, the NextCell operation were subject to a regular inspection by the Medical Products Agency which resulted in the wholesale dist...
Read moreRead more2019-12-04
Promising Results from clinical trial with ProTrans stem cells
NextCell Pharma AB ("NextCell") announces today that the primary efficacy measures have reached significance in the dose-escalation phase of the company’s clinical trial. After one year follow-up, the six patients treated with high- and medium-dose have retained their insulin production significantly better (P <0.01) as compared to the three patients who received a low-dose of the company's stem cell based drug candidate ProTrans. No serious side effects have been reported.
"The results very are promising, even though there are only few patients and this part of the clinical trial was an
NextCell Pharma AB ("NextCell") announces today that the primary efficacy measures have reached significance in the dose-escalation phase of the company’s clinical trial. After one year follow-up, the six patients treated with high- and medium-dose have retained their insulin production significa...
Read moreRead more2019-11-22
A part of Vision-driven Health
NextCell Pharma AB ("NextCell") announces that it is chosen as one of the collaborators in the newly Vinnova funded project Vision-driven Health: Sweden a leader in advanced therapies in 2030.
Vinnova is investing in establishing five vision-driven innovation environments to meet important health challenges. These include zero vision for malnutrition in the elderly, elimination of cancer as a cause of death and counteracting antibiotic resistance.
NextCell is participating in one of the approved five projects: Sweden a leader in advanced therapies in 2030. This project which is
NextCell Pharma AB ("NextCell") announces that it is chosen as one of the collaborators in the newly Vinnova funded project Vision-driven Health: Sweden a leader in advanced therapies in 2030.
Vinnova is investing in establishing five vision-driven innovation environments to meet important health...
Read moreRead more2019-11-07
Correction: Notice to attend the Annual General Meeting
NextCell Pharma AB ("NextCell") announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published. Compared to the press release published this morning, corrections have been made regarding the Market Abuse Regulation label. The information is not subject to the Market Abuse Regulation.
The annual general meeting will be held on December 5, 2019 at 10.00 at Novum, Hälsovägen 7, Huddinge. The notice has been published in Svenska Dagbladet and Post and Inrikes Tidningar as well as on the company's website, www.nextcellpharma.com.
The Annual Report and
NextCell Pharma AB ("NextCell") announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published. Compared to the press release published this morning, corrections have been made regarding the Market Abuse Regulation label. The information is not subject t...
Read moreRead more2019-11-07
Notice to attend the Annual General Meeting
NextCell Pharma AB ("NextCell") announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published.
The annual general meeting will be held on December 5, 2019 at 10.00 at Novum, Hälsovägen 7, Huddinge. The notice has been published in Svenska Dagbladet and Post and Inrikes Tidningar as well as on the company's website, www.nextcellpharma.com.
The Annual Report and Audit Report will be available three weeks before the Meeting, November 14, on the Company's website, www.nextcellpharma.com.
This information is the information that NextCell Pharma AB
NextCell Pharma AB ("NextCell") announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published.
The annual general meeting will be held on December 5, 2019 at 10.00 at Novum, Hälsovägen 7, Huddinge. The notice has been published in Svenska Dagbladet and ...
Read moreRead more2019-10-31
Year-end report 2018-09-01 - 2019-08-31
Nextcell Pharma AB ("NXTCL") today announces the year-end report for the 2018/2019 fiscal year (2018-08-31 2019-08-31)
Twelve months (2018-09-01 until 2019-08-31)
· Operating income amounted to SEK 1 964 132 (655 413).
· Operating result amounted to SEK -21 450 784 (-14 032 294).
· Earnings per share* amounted to SEK -1.36 (-0.61).
· Cash and bank amounted to SEK 20 128 185 (3 115 876).
· Solidity** amounted to 85.9 (59.2) %.
Fourth quarter (2019-06-01 until 2019-08-31)
· Operating income amounted to SEK 551 708 (127 868).
· Operating result
Nextcell Pharma AB ("NXTCL") today announces the year-end report for the 2018/2019 fiscal year (2018-08-31 2019-08-31)
Twelve months (2018-09-01 until 2019-08-31)
· Operating income amounted to SEK 1 964 132 (655 413).
· Operating result amounted to SEK -21 450 784 (-14 032 294). ...
Read moreRead more